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Objective. To evaluate the ethics of performing research in the ﬁeld of maternal-fetal medicine involving women undergoing
pregnancy termination. Methods. We identiﬁed published pharmacological studies performed during elective pregnancy
termination.Inaddition,aquestionnairewasadministeredtoinvestigatewhetherthisresearchwouldbeacceptabletoprofessionals
performing research in the ﬁeld of maternal-fetal pharmacology. Results. The majority of participants believe that this form
of research is necessary to furthering our understanding of drug use in pregnancy. Twenty studies were identiﬁed in women
undergoing a pregnancy termination where exogenous drug was administered and drug measurement conducted during an
abortion. The majority of studies were completed by international groups and not in North America or Western Europe.
Conclusions. While a majority of respondents to the survey felt that, although research in women undergoing a pregnancy
termination is ethically acceptable, 40% stated that it is not likely to be approved by institutional review boards of most North
American medical institutions.
1.Introduction
Approximately 50% of pregnancies are unplanned [1]o f t e n
making drug exposure in the ﬁrst trimester unintentional.
However, once a pregnant woman becomes aware of her
pregnancy, a series of ethical and legal dilemmas surface.
In many cases, the lack of information on safety of speciﬁc
drugs in pregnancy is a problem when deciding on drug al-
ternatives to treat or modify therapy in pregnant patients.
The information regarding teratogenicity obtained in
experimentalanimal modelsisusuallydiﬃculttoextrapolate
to clinical decision. Most drugs that have exhibited terato-
genic eﬀects in humans have also been proven to be terato-
genicin animal models [2],butnotalldrugswithproventer-
atogenicity in animal models have been found to be human
teratogens [2].
Ex vivo,human placental studieshave proven to be inval-
uable tools to answer questions regarding the trans-placental
transfer of drugs [2]. However, since the ex vivo model uses
placentas obtained at delivery, it often cannot necessarily
provideusefulinformation with regards totheﬁrst orsecond
trimesters of pregnancy. Clinical experience is therefore
critical to understand the complexity of drug behavior in
pregnancy.
Because ethical challenges have made it diﬃcult to study
drug safety in pregnant women, an intriguing line of clinical
research has been conducted over the last 4 decades in
women undergoing pregnancy termination. This research,
conducted worldwide, has focused on the study of the
aborted fetus with regards to drug absorption and disposi-
tion. The objective of the present study was to systematically
identify studies performed in women undergoing pregnancy
termination where biologicalsamples were obtained in order
to investigate transplacental drug transfer. Subsequently, we
aimed to evaluate the attitudes of scientists and physi-
cians practicing in the ﬁeld of maternal-fetal medicine with2 Obstetrics and Gynecology International
regards to studies involving women undergoing pregnancy
termination.
2.Methods
2.1. Systematic Review. Search was performed in Pubmed-
Medline and M-Base for studies in women undergoing vol-
untary pregnancy termination who received a drug not
aimed for their health. Search limits included a date span
from January 1964 to 2006 and only English articles were
included.
2.2. Survey. To investigate the attitudes of health profes-
sionals on ethical aspects of research in pregnant women
prior, duringand after abortion,we designed aquestionnaire
consisting of 2 hypothetical case studies. The ﬁrst addressed
the acceptability sampling of amniotic protein levels during
an abortion, while a second case described a study of the
administration of the antiretroviral drug, zidovudine, to a
w o m a nu n d e r g o i n ga na b o r t i o ni n f e c t e dw i t hH I V .T h e
questionnaire collected data on genderand country of origin
of the participants, as well as an open comments section to
express personal views on the acceptability of the presented
studies was oﬀered. Participants were asked if such proce-
dures would be acceptable in the diﬀerent trimesters of preg-
nancy, single versus multiple dose of drug administration
to the mother, and whether their institutional ethics board
would approve such research protocols.
Questionnaires were distributed during two maternal-
fetal pharmacology workshops, in Denver, Colo, USA, and
Toronto, ON, USA. Participants included both basic and
clinical scientists performing research in the area of mater-
nal-fetal medicine and toxicology. Participation was volun-
tary and this study received ethical approval by The Hospital
for Sick Children’s research ethics board.
3.Results
3.1.SystematicReview. Twentystudieswereidentiﬁed,where
a drug was intentionally administered to a woman undergo-
ing an abortion. One forensic report of a woman exposed to
heroin in pregnancy was also included (Table 1). Of them, 6
(28.6%)wereperformed inthe70’s,4(19%)wereperformed
in the 80’s, 6 (28.6%) were performed in the 90’s, and 5
(23.8%)inthe2000’s.Onlyfour(19%)studieswere reported
from North America, and all were reported between 1977
and 1983 whereas 17 (81%) studies were performed in other
partsoftheworld.The studiedexogenouscompoundsvaried
from ethanol and glucose to therapeutic drugs. The route of
administration to the mother was mainly oral. Nine (42.9%)
of the studies evaluated multiple-dose administration and 8
(38.1%)evaluateda single doseofthe exogenouscompound.
Of the 21 studies, 5 (23.8%) included women in the ﬁrst
trimester, 7 (33.3%) included in the second trimester, 8
(38.1%) included women in the 1st-2nd trimesters, and
only one study reported on women in the last trimester of
pregnancy.
Table 1: Studies where exogenous drug was administered and sam-
pledfromwomenandtheirabortuspriortopregnancytermination.
Reference Year Country Xenobiotic
[3] 2005 Hong Kong Rosiglitazone
[4] 2002 Hong Kong Naproxen
[5] 2002 Israel (15S)-15Methyl PG
F2alpha
[6] 2002 Belgium ans UK
and Madrid
Cefoxitin,
moxalactam and
ceftazidime
[7] 1999 Belgium and UK Glucose
[8] 1999 France Diclofenac
[9] 1998 Belgium and UK Fentanyl
[10] 1996 Belgium and UK Diazepam
[11] 1993 Belgium and UK Fentanyl
[12] 1993 Germany Thyroxine
[13] 1983 Canada Ethanol
[14] 1980 Finland Oxazepam
[15] 1978 Czech Sodium salicylate
[16] 1977 USA Cefazolin
[17] 1977 USA Amikacin
[18] 1997 UK Inulin
[19] 1977 USA Tobramycin
[20] 1999 USA Heroin
[21] 1975 Singapore Thiamphenicol
GA:gestationalage; IRB: ethicsapproval obtained; Consent:clearlydeclared
consent obtained; Mat: maternal blood samples; Fetal: fetal blood samples
obtained; Amniotic: amniotic/celomic samples obtained; FT: fetal tissue
collected and sampled.
Excluding the forensic case, 6 (30%) studies did not de-
clare ethics approval from their institutions and 3 (15%)
studies did not mention obtaining informed consent from
the participants.
3.2. Survey. Fifty participants responded to theadministered
questions (26 women and 24 men). In such a protocol with
56.0% preferring to conduct the study in the ﬁrst trimester,
21% in the second trimester, and 27.0% at anytime during
pregnancy. In response to the scenario of exogenous drug
administration, 34 (69%) respondents considered the study
designasacceptable.Ofthem,menandwomendidnotdiﬀer
in their responses. Participants preferred to conduct the
study in 1st-trimester abortions (42%), while the options of
second trimester (17%) or anytime during pregnancy (31%)
were lessfavored.With regards todosing,55%ofparticipants
preferred a single dose administration.
Of interest, 39.0% of participants, while considering the
proposed research to be useful, believed that their institu-
tional review boards were likely not to approve the design.
Another 39.0% of participants (50.0% men and 30.0%
women) considered that this type of research would be “too
controversial.” Finally, 20.0% of participants, all women,
indicated that they would not perform this research because
offearofcriticismleavingtheremaining 11%ofparticipants,Obstetrics and Gynecology International 3
who would not perform this research because of personal
reasons.
4.Discussion
In this study, we sought to investigate whether clinical trials
in women undergoing pregnancy termination are ethically
viable for the assessment of safety and transplacental drug
transport in pregnancy. This is the ﬁrst study to system-
atically review this topic and collect data on the attitudes
of researchers regarding the ethical standards necessary to
perform pharmacokinetic trials in women undergoing preg-
nancy termination.
The systematic review identiﬁed 20 studies of fetal drug
distribution in women undergoing pregnancy termination
performed since the 1970’s. Studies of exogenous com-
pounds were performed largely outside of North America
between the 80’s and 90’s. The lack of North American
abortiveresearchmaybeduetodissimilarattitudesregarding
abortion as compared to Europe or Asia. For example, in
Sweden, legal abortion is a recurrent part of a gynecologists’
work. A survey of Swedish gynecologist found that almost all
believed that gynecologists should be involved in abortion
care and half were opposed to the privilege of refusing to
work with termination of pregnancy [22]. Alternatively, it
hasbeensuggestedthatthelackofNorthAmericanstudiesin
theabortuspopulationmaybeduetotheethicalstandardsin
north American institutions becoming more stringent with
the advent of fetal tissue research and in utero fetal surgery.
Of importance, 30% of those studies, despite the utmost
sensitivity of the clinical situation, do not mention approval
by the local ethics committee. Such approval is a legal and
ethical prerequisite in all countries where these studies had
been performed.
Our survey of the attitudes of North American research-
ers towards research in women undergoingabortion suggests
that the majority of researchers in maternal-fetal medicine
would respond positively to performing studies in women
undergoing a pregnancy termination. Their opinions were
not diﬀerent from those of surveyed women [23]. According
to Anderson et al., 94% of women feel that fetal tissue
research was justiﬁable and 84% say they would allow this
sort of research to be done on their own fetus [23]. In fact,
this same study [23] found that, while few women felt that
research on a live fetus was justiﬁable, signiﬁcantly more
women (68%) about to undergo termination of pregnancy
found this idea acceptableand more than half ofthem would
have permitted research to be carried out on their own
live fetus [23]. Our present survey results are in agreement
with those of Anderson et al. [23]. Both women about to
undergo an abortion and our surveyed health professionals
were in agreement with regards to the value of studies and
information that may results from studies in the abortive
population.
Overwhelmingly, the opinion of our surveyed profes-
sionals was that this type of research was useful butlikely not
to be approved by their respective institutions. The common
fear was that such a study design would be too controversial.
However, pregnancy is a dynamic state that can only be
compared to itself. Without the participation of pregnant
women themselves, safe and eﬀective use of drugs during
this critical period in a women’s life will in no way become
a reality. However, the abortive population presents itself as
a relevant pharmacological comparison, to be used as an
investigational population for drugs in pregnancy without
the risk of any fetal adverse consequences.
The open comments section of the survey was the most
informative with regards to justiﬁcations against research in
women undergoing pregnancy terminations. The most per-
tinent reason was with regards to the quality of consent
that can practically be achieved in a women undergoing
pregnancy termination.
SincetheNurembergCode,ithasbeenwidelyestablished
that ethical consent cannot be obtained from a patient who
is under coercion, threat, or duress [24]. With regards to
abortion, it could be argued that the consent process is in
itself intrinsically coercive due to the emotional nature of the
situation [25]. It has been suggested that women would be
more likely to consent to participate in research as a way
to alleviate their feelings of guilt surrounding the abortion
[23]. Currently, in order to improve the quality of consent
in the abortive population, the objective has been to achieve
a practical separation of the abortion and the subsequent
use of human fetal tissue [23]. The same should apply to a
woman’s decision to enroll in a pharmacokinetic study. In
fact, Bopp Jr. observed that most women were ambivalent
about abortion, with 5% changing their minds after making
the abortion appointment [26].
As such, the Human Fetal Tissue Transplantation Re-
search (HFTTR) panel recommended that a woman should
not be asked for her consent to participate in a study until
she has decided to obtain an abortion [8]. If such research
is to happen, the women should be recruited by a recruiter
not aﬃliated with the abortion clinic, capable of assessing
the women’s capacity to consent, considering her level of
education,languagecomprehension,andculturaladaptation
to an authority ﬁgure (i.e., doctor) making the request. The
hopeisthatanindependentrecruiterwillcircumventtherisk
of coercion by separating the “source” (the patient providing
the samples) and the “user” (the researcher employing the
samples) [27].
In addition, the consent process should be value neutral,
neither approving nor disapproving of the practice of abor-
tion. Thus, the consent process should be nondirective and
noncoercive [27]. Chervenak et al. [27] have suggested that
words such as “treatment” and “therapy” should not be used
by the investigator to describe the intervention. Words such
as “mother, father, and baby” should not be used because
these suggest moral relationships. Instead, it is preferable to
use words such as “pregnant woman” and “abortus.” The
consent form should also contain explicit details about the
nature of the procedure, including the risks regarding future
pregnancyandpostpartummanagement followingthestudy.
A related recommendation, then, is that researchers should
routinely test the participating woman’s understanding of
risk for the individual study, a practice endorsed by many
and practiced by few. Autonomous decision making is a core4 Obstetrics and Gynecology International
requirement of ethical research. Vigilance about minimizing
and managing study risks is likely the best protection volun-
teers can have [28].
There were several limitations to this study. Firstly, there
were 50 respondents recruited predominantly at 2 academic
meetings in NorthAmerica.This mighthavecreated abias as
those likely not to participate at meetings may have diﬀerent
views and may less likely approve such a protocol. Secondly,
interviewing a larger, more heterogeneous study population
will help to conﬁrm or reject our ﬁndings. Finally, by design,
this was not a prevalence study. Targeting enrollment in
this way did not allow examination of questions related to
prevalence.
5.Conclusions
We have identiﬁed published studies investigating the trans-
placental pharmacology in women undergoing abortion and
have discussed some of their ethical implications. Progress
in pregnancy drug use, design, and testing can only be made
possiblethroughtheparticipationofpregnant womenthem-
selves.Itisofinterestthatveryfewofthemwereconductedin
North America in the last decade, while this type of research
has been practiced in diﬀerent parts of the world. The ability
to test an abortus and fetal tissue is arelatively novel strategy,
acceptedby themajority ofsurveyedwomen and scientistsin
the ﬁeld of maternal fetal pharmacology. It is our contention
that the North American discomfort with the use of the
abortive population, ingrained in our scientiﬁc institutions,
will hinder our ability to improve drug safety and treatment
in maternal-fetal pharmacology. The potential information
gained from conducting such studies may be important to
bridging the knowledge gap in terms of drug behavior in
pregnant women and providing the necessary information
to alleviate fears of prescribing drugs in pregnancy. In this
way,theexperienceofabortusresearchhasthepotentialtobe
transformed into a life-saving opportunity for future fetuses.
Yet the extreme vulnerability and sensitivity of the woman
during this time dictates that continued discussion of the
risks, beneﬁts, and quality of consent continue to take place.
Much larger debate should ensue to try to resolve these
issues.
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